Advertisement

Topics

Aimmune’s peanut allergy drug meets primary endpoint in Phase III trial

08:18 EDT 26 Mar 2019 | Pharmaceutical Technology

Food allergy-focused Aimmune Therapeutics has announced its peanut allergy drug AR101 met its primary endpoint in Phase III European clinical...
Read More...

The post Aimmune’s peanut allergy drug meets primary endpoint in Phase III trial appeared first on Pharmaceutical Technology.

Original Article: Aimmune’s peanut allergy drug meets primary endpoint in Phase III trial

NEXT ARTICLE

More From BioPortfolio on "Aimmune’s peanut allergy drug meets primary endpoint in Phase III trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Food
Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

Allergies
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...